Makers of a new type of cholesterol drug might not have to demonstrate that the drugs reduce the risk of heart attack and stroke, under new FDA guidance. The companies would instead have to prove only that the drugs work to lower harmful forms of cholesterol. The drugs, known as PCSK9 inhibitors, are meant to block a protein that maintains low-density lipoprotein in the bloodstream.

Full Story:

Related Summaries